Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

被引：6
|
作者：
Marascio, Nadia [1 ]
Mazzitelli, Maria [2 ]
Pavia, Grazia [1 ]
Giancotti, Aida [1 ]
Barreca, Giorgio Settimo [1 ]
Costa, Chiara [2 ]
Pisani, Vincenzo [2 ]
Greco, Giuseppe [2 ]
Serapide, Francesca [2 ]
Trecarichi, Enrico Maria [2 ]
Casalinuovo, Francesco [3 ]
Liberto, Maria Carla [1 ]
Matera, Giovanni [1 ]
Torti, Carlo [2 ]
机构：
[1] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Unit Clin Microbiol, I-88100 Catanzaro, Italy
[2] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Unit Infect & Trop Dis, I-88100 Catanzaro, Italy
[3] Inst Expt Vet Med Southern Italy, I-88100 Catanzaro, Italy
来源：
CELLS | 2019年 / 8卷 / 05期
关键词：
pediatric patients; Hepatitis C virus 4; sofosbuvir; ledipasvir; RESISTANCE-ASSOCIATED SUBSTITUTIONS; TRANSMISSION; SOFOSBUVIR;
D O I：
10.3390/cells8050416
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients treated with fixed-dose combination of sofosbuvir/ledipasvir, already approved to treat HCV4 genotype. Both young girls achieved SVR even though HCV4 isolates carried L28M and M31L NS5A resistance-associated substitutions (RASs). Therefore, possible effects of these RASs merit further study, especially in children.
引用
收藏
页数：9
相关论文
共 50 条
  • [31] Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1
    Naggie, Susanna
    Cooper, Curtis
    Saag, Michael
    Yang, Jenny C.
    Stamm, Luisa M.
    Pang, Philip S.
    McHutchison, John G.
    Dieterich, Douglas
    Sulkowski, Mark S.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [32] Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1
    Bhagani, S.
    Naggie, S.
    Cooper, C.
    Saag, M.
    Yang, J.
    Stamm, L.
    Pang, P.
    McHutchison, J.
    Troke, P.
    Dieterich, D.
    Sulkowski, M.
    [J]. HIV MEDICINE, 2015, 16 : 31 - 31
  • [33] Variability of selected extracellular matrix proteins concentrations in HCV infected patients treated with sofosbuvir and ledipasvir
    Kozlowska, Agata
    Tomasiewicz, Krzysztof
    Krzowska-Firych, Joanna
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E226 - E227
  • [34] Sofosbuvir plus Ribavirin in the Treatment of Egyptian Patients with Chronic Genotype 4 HCV Infection
    Esmat, Gamal E.
    Shiha, Gamal
    Omar, Rabab F.
    Hassany, Mohamad
    Hammad, Radi
    Khairy, Marwa
    Samir, Waleed
    Soliman, Reham
    Brainard, Diana M.
    Jiang, Deyuan
    Kersey, Kathryn
    Knox, Steven J.
    Massetto, Benedetta
    McHutchison, John G.
    Doss, Wahid H.
    [J]. HEPATOLOGY, 2014, 60 : 662A - 663A
  • [35] Sofosbuvir plus Ribavirin in the Treatment of Egyptian Patients with Chronic Genotype 4 HCV Infection
    Doss, Wahid H.
    Ruane, Peter J.
    Shiha, Gamal
    Ain, Dani
    Soliman, Reham
    Khairy, Marwa
    Hassany, Mohamad
    Riad, Joseph
    Samir, Waleed
    Omar, Rabab F.
    Hammad, Radi
    Meshrekey, Raymond
    Gamil, Mostafa
    Jiang, Deyuan
    Massetto, Benedetta
    Knox, Steven J.
    Kersey, Kathryn
    McHutchison, John G.
    Esmat, Gamal E.
    [J]. HEPATOLOGY, 2015, 62 : 737A - 738A
  • [36] Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
    Gane, Edward J.
    Hyland, Robert H.
    An, Di
    Svarovskaia, Evguenia
    Pang, Phillip S.
    Brainard, Diana
    Stedman, Catherine A.
    [J]. GASTROENTEROLOGY, 2015, 149 (06) : 1454 - +
  • [37] Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients
    Maasoumy, Benjamin
    Buggisch, Peter
    Mauss, Stefan
    Boeker, Klaus H. W.
    Mueller, Tobias
    Guenther, Rainer
    Zimmermann, Tim
    Manns, Michael P.
    Sarrazin, Christoph
    Hueppe, Dietrich
    Wedemeyer, Heiner
    Vermehren, Johannes
    [J]. LIVER INTERNATIONAL, 2018, 38 (11) : 1906 - 1910
  • [38] Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors
    Kanda, Tatsuo
    Yasui, Shin
    Nakamura, Masato
    Suzuki, Eiichiro
    Arai, Makoto
    Ooka, Yoshihiko
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Saito, Tomoko
    Haga, Yuki
    Takahashi, Koji
    Sasaki, Reina
    Wu, Shuang
    Nakamoto, Shingo
    Tawada, Akinobu
    Maruyama, Hitoshi
    Imazeki, Fumio
    Kato, Naoya
    Yokosuka, Osamu
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [39] Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient
    Sollima, Salvatore
    Antinori, Spinello
    Torre, Alessandro
    Binda, Francesca
    Giacomelli, Andrea
    Milazzo, Laura
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (08) : 838 - 840
  • [40] SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAIVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY
    Kowdley, K. V.
    Stuart, G. C.
    Reddy, R. K.
    Rossaro, L.
    Bernstein, D. E.
    An, D.
    Svarovskaia, E. S.
    Hyland, R. H.
    Pang, P. S.
    Symonds, W. T.
    Mchutchison, J. G.
    Muir, A. J.
    Pockros, P. J.
    Pound, D.
    Fried, M. W.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S23 - S24
12345